Questions Surround Some DMD Drugs; More Near U.S. Market

Since 2016, the FDA has approved a handful of therapies to treat Duchenne muscular dystrophy (DMD). But some uncertainty exists over their effectiveness, in addition to concerns about their costs. Additional products may be available soon, as the pipeline for the condition boasts several candidates.

According to the National Institute of Neurological Disorders and Stroke, muscular dystrophy consists of a group of more than 30 genetic diseases in which people lose muscle mass and strength over time. DMD, which mainly affects boys and is caused by a lack of dystrophin, is the most common form of the condition, accounting for about half the cases. Onset of the progressive disease is between 3 years old and 5 years old. Most boys with the condition will not be able to walk by the time they’re 12 years old. They will experience declining heart and lung functions and will require a respirator. People with the condition usually die in their 40s.

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

a-businessman-touching-screen
May 12

Do Pharma/PBM Contracts Play Role in Drugmakers’ Revenue Leakage?

READ MORE
a-doctor-speaking-to-a-patient
May 12

Novartis’ Pluvicto Brings New Mechanism of Action to mCRPC Options

READ MORE
an-elderly-looking-outside
May 12

Study Finds PBC Drug’s Real-World, Trial Side Effects Are Similar

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today